Compugen SVP granted stock options and RSUs

COMPUGEN LTD SVP, Business Development Zurit Levine reported equity awards.

Rhea-AI Filing Summary

COMPUGEN LTD SVP, Business Development Zurit Levine reported equity awards. The insider received 18000.0000 restricted stock units and 24000.0000 share options at an exercise price of 2.2600 per share, each vesting 25% on September 30, 2027 and the remainder in 12 equal quarterly installments, contingent on continued service, resulting in 47375.0000 ordinary shares held directly.

Insider Trade Summary

Grant/Award: 42,000 shares

Grant/Award 2 txns

Insider Levine Zurit

Role SVP, Business Development

Type	Security	Shares	Price	Value
Grant/Award	Share Option (right to buy) F2	24,000	$0.00	$0.00
Grant/Award	Ordinary Shares F1	18,000	$0.00	$0.00

Holdings After Transaction: Share Option (right to buy) — 24,000 contracts (Direct); Ordinary Shares — 47,375 shares (Direct)

Footnotes (2)

1. F1. Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
2. F2. This option vests 25% on September 30, 2027 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

Key Figures

RSU Award: 18000.0000 shares Share Options Granted: 24000.0000 options Option Exercise Price: 2.2600 per share +3 more

6 metrics

RSU Award 18000.0000 shares Restricted stock unit award granted on 2026-07-29

Share Options Granted 24000.0000 options Share Option (right to buy) granted on 2026-07-29

Option Exercise Price 2.2600 per share Conversion or exercise price for share options

Option Expiration 2036-07-29 Expiration date of granted share options

Ordinary Shares After Award 47375.0000 shares Direct ordinary share holdings following RSU acquisition

Initial Vesting Date 2027-09-30 25% of RSUs and options vest on this date

Key Terms

restricted stock unit ("RSU"), Share Option (right to buy), quarterly installments

3 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") award."

Share Option (right to buy) financial

"security_title: Share Option (right to buy)"

quarterly installments financial

"the remainder vests in 12 equal quarterly installments thereafter"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did COMPUGEN LTD (CGEN) report for Zurit Levine?

Zurit Levine reported two equity awards: 18000.0000 restricted stock units in ordinary shares and 24000.0000 share options, both granted on 2026-07-29, with structured vesting over several years.

How many RSUs did COMPUGEN LTD (CGEN) grant to Zurit Levine?

COMPUGEN LTD granted Zurit Levine 18000.0000 restricted stock units. The award vests 25% on September 30, 2027, with the remaining 75% vesting in 12 equal quarterly installments, subject to continued service to the company.

What are the key terms of Zurit Levine’s share options at COMPUGEN LTD (CGEN)?

Zurit Levine received 24000.0000 share options with an exercise price of 2.2600 per share, expiring on 2036-07-29. The options vest 25% on September 30, 2027 and the remainder in 12 equal quarterly installments, contingent on continued service.

What is Zurit Levine’s COMPUGEN LTD (CGEN) shareholding after these awards?

Following the reported awards, Zurit Levine directly holds 47375.0000 ordinary shares. This figure reflects the updated direct ownership position after the 18000.0000 RSU grant recorded as an acquisition.

When do Zurit Levine’s RSUs and options at COMPUGEN LTD (CGEN) start vesting?

Both the RSU award and share options begin vesting on September 30, 2027. After an initial 25% vest, the remaining portion vests in 12 equal quarterly installments, assuming continued service with COMPUGEN LTD.

Were Zurit Levine’s COMPUGEN LTD (CGEN) awards under a Rule 10b5-1 plan?

The Form 4’s Rule 10b5-1 checkbox was not marked. The data indicates the equity awards were reported as grants or awards, with no affirmation that they were made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/30/2026 - 04:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levine Zurit

(Last) (First) (Middle)

C/O COMPUGEN LTD.

26 HAROKMIM STREET

(Street)

HOLON 5885849

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
COMPUGEN LTD [ CGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Business Development

2a. Foreign Trading Symbol
[CGEN]

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/29/2026		A		18,000(1)	A	$0	47,375	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$2.26	07/29/2026		A		24,000		(2)	07/29/2036	Ordinary Shares	24,000	$0	24,000	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

2. This option vests 25% on September 30, 2027 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

	/s/ Zurit Levine	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)